End-stage renal disease
Conditions
Interventions
Control group:None
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, any gender; 2. Diagnosed with type 2 diabetes; 3. Meets ESRD diagnosis: eGFR = 3 months, with complete clinical data during the treatment period.
Exclusion criteria
Exclusion criteria: 1.Presence of contraindications to semaglutide use: history or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2 (MEN2), history of acute pancreatitis, or severe gastrointestinal disorders (e.g., gastroparesis, intestinal obstruction); 2.Complicated with severe comorbidities: heart failure, active malignant tumor, severe hepatic insufficiency (Child-Pugh Class C), severe infection (e.g., sepsis), or acute kidney injury; 3.Hypersensitivity to semaglutide or any component of its pharmaceutical formulation; 4.Incomplete clinical data that prevent the extraction of primary outcome indicators (e.g., glycated hemoglobin [HbA1c]).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in HbA1c levels before and 3 months after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in UACR, body weight, BMI, and lipid profile (TG, TC, LDL-C) before treatment and at 3 and 6 months after treatment; | — |
Countries
China
Contacts
Public ContactJiali Jiang
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
Outcome results
None listed